Moody Aldrich Partners LLC Acquires Shares of 29,614 Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Moody Aldrich Partners LLC acquired a new stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 29,614 shares of the company’s stock, valued at approximately $1,331,000. Moody Aldrich Partners LLC owned about 0.07% of Soleno Therapeutics as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Janus Henderson Group PLC increased its stake in shares of Soleno Therapeutics by 21.5% in the 3rd quarter. Janus Henderson Group PLC now owns 4,081,099 shares of the company’s stock valued at $206,016,000 after purchasing an additional 722,226 shares in the last quarter. Nantahala Capital Management LLC increased its stake in shares of Soleno Therapeutics by 27.9% in the 2nd quarter. Nantahala Capital Management LLC now owns 3,082,107 shares of the company’s stock valued at $125,750,000 after purchasing an additional 671,728 shares in the last quarter. FMR LLC increased its stake in shares of Soleno Therapeutics by 6,048,754.5% in the 3rd quarter. FMR LLC now owns 665,374 shares of the company’s stock valued at $33,595,000 after purchasing an additional 665,363 shares in the last quarter. Westfield Capital Management Co. LP purchased a new position in shares of Soleno Therapeutics in the 3rd quarter valued at about $25,028,000. Finally, Wellington Management Group LLP increased its stake in shares of Soleno Therapeutics by 73.8% in the 3rd quarter. Wellington Management Group LLP now owns 683,170 shares of the company’s stock valued at $34,493,000 after purchasing an additional 290,135 shares in the last quarter. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Stock Performance

SLNO opened at $48.98 on Wednesday. Soleno Therapeutics, Inc. has a one year low of $36.61 and a one year high of $60.92. The stock has a market capitalization of $2.11 billion, a PE ratio of -14.75 and a beta of -1.47. The business’s 50 day moving average price is $48.19 and its 200 day moving average price is $49.78.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($1.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($1.22). As a group, equities research analysts forecast that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.

Insider Activity at Soleno Therapeutics

In other Soleno Therapeutics news, insider Kristen Yen sold 2,340 shares of the company’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $46.18, for a total transaction of $108,061.20. Following the transaction, the insider now directly owns 76,605 shares in the company, valued at $3,537,618.90. This represents a 2.96 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bhatnagar Anish sold 10,937 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $45.41, for a total value of $496,649.17. Following the transaction, the chief executive officer now owns 708,616 shares in the company, valued at $32,178,252.56. This trade represents a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 17,360 shares of company stock worth $790,119. Insiders own 12.30% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on SLNO shares. Robert W. Baird restated an “outperform” rating and issued a $72.00 price target on shares of Soleno Therapeutics in a research note on Monday, December 2nd. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Soleno Therapeutics in a research note on Monday, December 2nd. Stifel Nicolaus reiterated a “buy” rating and set a $74.00 price objective on shares of Soleno Therapeutics in a research note on Monday, December 2nd. Finally, Oppenheimer boosted their price objective on Soleno Therapeutics from $65.00 to $73.00 and gave the stock an “outperform” rating in a research note on Monday, October 28th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $74.83.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.